About The Study: In this post hoc analysis, the dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.
Corresponding Author: To contact the corresponding author, Steven E. Nissen, MD, email nissens@ccf.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2026.0767)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American College of Cardiology 75th Annual Scientific Session & Expo.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.0767?guestAccessKey=9d185a50-119b-4cb8-a1eb-05fd89318415&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032826
JAMA Cardiology